At the 2026 Collaborative Community on Ophthalmic Innovation (CCOI) Asia-Pacific Innovation Forum and the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong, EssilorLuxottica played a leading role in advancing the global scientific dialogue on myopia management and ophthalmic innovation.

Across both forums, discussions reflected a clear evolution in the field: from focusing solely on slowing myopia progression to embracing a broader, prevention-oriented and future-focused strategy grounded in clinical evidence, access, and cross-sector collaboration. Through high-level scientific contributions and new clinical data presentations, the Group reinforced its ambition to expand the myopia toolkit and strengthen standards of care worldwide.

CCOI: Advancing Standards and Scientific Ambition

CCOI convened clinicians, researchers, regulators and industry leaders to align scientific priorities and long-term innovation in ophthalmology. EssilorLuxottica actively supported this collaboration and contributed to shaping the agenda around myopia and emerging technologies.

During Myopia Day, the Group outlined the industry’s instrumental role in expanding the myopia management toolkit. Building on today’s first-line solutions, it presented a long-term scientific ambition that looks toward next frontiers, including research exploring the potential to ultimately stop progression and prevent or significantly delay myopia onset. Access, evolving standards of care, collaboration, and AI-enabled innovation were emphasized as key enablers of future progress.

In a session on lens-based innovation, clinical perspectives were shared on evidence-based spectacle interventions within a comprehensive management framework. Emerging strategies to delay myopia onset and improve efficacy across the continuum of care were highlighted, referencing Essilor Stellest lenses† as an example of science-driven optical innovation.

On Innovation Day, the intersection between myopia and glaucoma was addressed, with a focus on early diagnostic challenges and the need for interoperable, multi-site data. Collaborative initiatives such as the Glaucoma Myopia OCT Phenotyping Consortium were referenced, reflecting efforts to improve assessment in complex cases where high myopia can confound glaucoma evaluation.

The transformative role of AI across optical solutions, wearables and medical technologies was also highlighted, underscoring the responsible integration of data-driven innovation to enhance clinical decision-making and patient outcomes.

APAO: Translating Evidence into Clinical Practice

APAO 2026 convened more than 11,000 eye care professionals from 111 countries, providing a global platform for evidence-based exchange.

At EssilorLuxottica’s sponsored symposium, a structured clinical roadmap for myopia management was presented, emphasizing early risk identification and personalized treatment strategies based on axial elongation.

Two-year results from a randomized clinical trial in pre-myopic children using H.A.L.T.* (Highly Aspherical Lenslet Target) technology demonstrated reduced axial eye growth associated with higher wearing time, reinforcing the importance of early and consistent intervention.

In addition, new data were presented on Essilor Stellest 2.0 lenses‡ featuring H.A.L.T.* MAX technology. Results from a 12-month randomized, contralateral crossover clinical trial in Singapore demonstrated significantly greater efficacy in slowing eye growth in myopic children compared with Essilor Stellest lenses,† nearly halving eye growth versus the previous generation. §1

A Continuing Education seminar held in collaboration with a local professional association engaged more than 600 eye care professionals, marking the introduction of spectacle lenses featuring H.A.L.T.* MAX technology in Hong Kong.

Advancing Vision Care Through Science and Collaboration

Through scientific leadership at CCOI and robust clinical engagement at APAO, EssilorLuxottica continues to advance professional education, evidence-based practice and responsible innovation in myopia management.

By connecting research, AI-enabled technologies, and global partnerships, the Group is driving a more proactive and comprehensive approach to myopia care, reinforcing the tools, standards, and collaboration required to support eye care professionals and enhance long-term patient outcomes worldwide.

Notes:

* H.A.L.T. Highly Aspherical Lenslet Target. H.A.L.T. is an acronym for Highly Aspherical Lenslet Target and does not imply a “halt” or “stop” of myopia progression.

† Essilor® Stellest® lens regulatory status and product availability may vary by country. U.S. FDA authorization and indications for use are based solely on clinical trial data from the U.S.

‡ Essilor® Stellest® 2.0 lenses are not currently available in all countries, including the U.S. and have not been cleared by the U.S. FDA.

§ Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 myopic children. The estimated cumulative 12-month axial length change (eye growth) was 0.228 mm with Essilor® Stellest® lenses and 0.121 mm with Essilor® Stellest® 2.0 lenses, corresponding to a 46 % relative reduction.

1. Raveendran RN, et al. Effect of increased power and asphericity of highly aspherical lenslets on myopia control efficacy: a contralateral crossover study. Transl Vis Sci Technol. 2025;14(11):9;